Investor Relations

Explore information about IDEAYA's business, strategy, pipeline, and financial performance, as well as the latest updates for the investment community.

Download IDEAYA Highlights

Stock Info
NASDAQIDYA

View all stock information

Recent News
Jun 17, 2026
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S. Hata, Chairman of the Board. Mr. Hata is...

Jun 15, 2026
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45...

Jun 10, 2026
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share,...

All Releases

Events
AI Panel at the 2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
8:45am EDT

Panel discussion featuring Yujiro S. Hata, President and Chief Executive Officer, moderated by Akash Tewari, Global Head of Biopharmaceutical Research

2026 Jefferies Global Healthcare Conference
Wednesday, June 3, 2026
7:35am EDT

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events